公开(公告)号：US20200231936A1

公开(公告)日：2020-07-23

申请号：US16725677

申请日：2019-12-23

Applicant: Mesoblast International Sárl

Inventor： Samson TOM ,  Christopher Ton ,  Alla Danilkovitch

IPC: C12N5/0775 ,  A61K47/69 ,  B82Y5/00 ,  A61K49/18 ,  A61K49/04 ,  A61K41/00 ,  A61K35/28

Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

公开(公告)号：US20240117315A1

公开(公告)日：2024-04-11

申请号：US18331353

申请日：2023-06-08

Applicant: Mesoblast International Sárl

Inventor： Samson TOM ,  Christopher TON ,  Alla DANILKOVITCH

IPC: C12N5/0775 ,  A61K35/28 ,  A61K41/00 ,  A61K47/69 ,  A61K49/04 ,  A61K49/18 ,  B82Y5/00

CPC classification number: C12N5/0663 ,  A61K35/28 ,  A61K41/0038 ,  A61K41/0052 ,  A61K47/6901 ,  A61K49/0423 ,  A61K49/1827 ,  B82Y5/00 ,  A61M37/00 ,  C12N2511/00

Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

公开(公告)号：US20230089901A1

公开(公告)日：2023-03-23

申请号：US17934852

申请日：2022-09-23

Applicant: Mesoblast International Sárl

Inventor： Alla DANILKOVICH ,  Robert E. NEWMAN ,  Samson TOM ,  Christopher TON ,  Zhanling WANG ,  Randell G. YOUNG

IPC: A61K35/28 ,  C12N5/0775

Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.